HIV viral suppression in the era of antiretroviral therapy
- 1Department of Infectious Diseases, Castle Hill Hospital, Cottingham, East Yorkshire
- 2Department of Infection and Tropical Medicine, University of Newcastle Medical School, Newcastle General Hospital, Newcastle upon Tyne
- Correspondence to: Dr H K Thaker, Department of Infectious Diseases, Castle Hill Hospital, Castle Road, Cottingham, East Yorkshire HU16 5JQ, UK; hiten.thaker{at}hey.nhs.uk
- Received 18 June 2002
- Accepted 1 October 2002
Abstract
Altogether 42 million people worldwide have been infected with HIV, and 12 million have died over the last 20 years. Effective antiretroviral therapy has lead to sustained HIV viral suppression and immunological recovery in patients who have been infected with the virus. The incidence of AIDS has declined in the Western world with the introduction of effective antiretroviral therapy. Questions on When to start treatment?, What to start with?, How to monitor patients?, remain heavily debated. Adherence to antiretroviral treatment remains the cornerstone of effective treatment, and failure to adhere is the strongest predictor of virological failure. Long term therapy can lead to metabolic complications. Resource poor countries are dealing with difficult issues such as mother to child prevention of HIV transmission. Other treatment options are now available, with the recent introduction of fusion inhibitors, second generation non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors to clinical practice.
- HAART, highly active antiretroviral therapy
- NNRTI, non-nucleoside reverse transcriptase inhibitor
- NRTI, nucleoside reverse transcriptase inhibitor
- PI, protease inhibitor







